Halperin SA - Search Results

1

Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.

Diaz-Mitoma F, Halperin SA, Tapiero B, Hoffenbach A, Zappacosta PS, Radley D, Bradshaw S, Martin JC, Boslego JW, Hesley TM, Bhuyan PK, Silber JL. Diaz-Mitoma F, et al. Among authors: halperin sa. Vaccine. 2011 Feb 1;29(6):1324-31. doi: 10.1016/j.vaccine.2010.11.053. Epub 2010 Dec 4. Vaccine. 2011. PMID: 21134456 Clinical Trial.

2

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children.

Halperin SA, Smith B, Mabrouk T, Germain M, Trépanier P, Hassell T, Treanor J, Gauthier R, Mills EL. Halperin SA, et al. Vaccine. 2002 Jan 15;20(7-8):1240-7. doi: 10.1016/s0264-410x(01)00428-5. Vaccine. 2002. PMID: 11803087 Clinical Trial.

3

Use of lidocaine-prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate and hepatitis B vaccines in infants from birth to six months of age.

Halperin BA, Halperin SA, McGrath P, Smith B, Houston T. Halperin BA, et al. Among authors: halperin sa. Pediatr Infect Dis J. 2002 May;21(5):399-405. doi: 10.1097/00006454-200205000-00010. Pediatr Infect Dis J. 2002. PMID: 12150176 Clinical Trial.

4

Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study.

Halperin SA, McDonald J, Samson L, Danzig L, Santos G, Izu A, Smith B, MacDonald N. Halperin SA, et al. Clin Invest Med. 2002 Dec;25(6):243-51. Clin Invest Med. 2002. PMID: 12516995 Clinical Trial.

5

Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine.

Halperin SA, Scheifele D, Mills E, Guasparini R, Humphreys G, Barreto L, Smith B. Halperin SA, et al. Vaccine. 2003 Jun 2;21(19-20):2298-306. doi: 10.1016/s0264-410x(03)00173-7. Vaccine. 2003. PMID: 12744860 Clinical Trial.

6

A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.

Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ. Halperin SA, et al. Vaccine. 2003 Jun 2;21(19-20):2461-7. doi: 10.1016/s0264-410x(03)00045-8. Vaccine. 2003. PMID: 12744879 Clinical Trial.

7

A pilot study to quantify parental anxiety associated with enrollment of an infant or toddler in a phase III vaccine trial.

Langley JM, Halperin SA, Smith B. Langley JM, et al. Among authors: halperin sa. Vaccine. 2003 Sep 8;21(25-26):3863-6. doi: 10.1016/s0264-410x(03)00304-9. Vaccine. 2003. PMID: 12922120 Clinical Trial.

8

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.

Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, Levitt D, Nest GV, Gennevois D, Eiden JJ. Halperin SA, et al. Vaccine. 2006 Jan 9;24(1):20-6. doi: 10.1016/j.vaccine.2005.08.095. Epub 2005 Sep 12. Vaccine. 2006. PMID: 16198027 Clinical Trial.

9

Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults.

Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, Mallett CP, Lowell GH, Fries L. Langley JM, et al. Among authors: halperin sa. Vaccine. 2006 Mar 6;24(10):1601-8. doi: 10.1016/j.vaccine.2005.09.056. Epub 2005 Oct 14. Vaccine. 2006. PMID: 16303215 Clinical Trial.

10

Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age.

Scheifele DW, Halperin SA, Smith B, Ochnio J, Meloff K, Duarte-Monteiro D. Scheifele DW, et al. Among authors: halperin sa. Vaccine. 2006 Mar 15;24(12):2057-64. doi: 10.1016/j.vaccine.2005.11.021. Epub 2005 Nov 28. Vaccine. 2006. PMID: 16356598 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

375 results

Search Page